Northwest Biotherapeutics, Inc. | 10-Q: FY2025 Q2 Revenue: USD 131 K

LB filings
2025.08.14 21:02
portai
I'm PortAI, I can summarize articles.

Revenue: As of FY2025 Q2, the actual value is USD 131 K.

EPS: As of FY2025 Q2, the actual value is USD -0.01.

Segment Revenue

  • Research and Other Revenue: For the three months ended June 30, 2025, revenue was $131,000, compared to $510,000 for the same period in 2024. For the six months ended June 30, 2025, revenue was $506,000, compared to $794,000 for the same period in 2024.

Operational Metrics

  • Net Loss: The net loss for the three months ended June 30, 2025 was $15.4 million, compared to $17.9 million for the same period in 2024. For the six months ended June 30, 2025, the net loss was $34.7 million, compared to $36.2 million for the same period in 2024.
  • Research and Development Expenses: For the three months ended June 30, 2025, R&D expenses were $7.4 million, compared to $8.3 million for the same period in 2024. For the six months ended June 30, 2025, R&D expenses were $15.8 million, compared to $16.2 million for the same period in 2024.
  • General and Administrative Expenses: For the three months ended June 30, 2025, G&A expenses were $7.5 million, compared to $9.7 million for the same period in 2024. For the six months ended June 30, 2025, G&A expenses were $16.8 million, compared to $17.8 million for the same period in 2024.

Cash Flow

  • Operating Cash Flow: Net cash used in operating activities for the six months ended June 30, 2025 was $16.1 million, compared to $28.6 million for the same period in 2024.
  • Investing Cash Flow: Net cash used in investing activities for the six months ended June 30, 2025 was $397,000, compared to $760,000 for the same period in 2024.
  • Financing Cash Flow: Net cash provided by financing activities for the six months ended June 30, 2025 was $24.2 million, compared to $29.2 million for the same period in 2024.

Unique Metrics

  • Convertible Notes at Fair Value: As of June 30, 2025, the fair value of convertible notes was $38.5 million, compared to $34.2 million as of December 31, 2024.

Future Outlook and Strategy

  • Core Business Focus: The company plans to continue its focus on the DCVax-L and DCVax-Direct programs, including preparations for Phase II trials and expansion of manufacturing capacity.
  • Non-Core Business: The company is exploring potential compassionate use programs in the US and expanding its existing program in the UK.
  • Priority: The company is actively engaged in the MAA process for DCVax-L in the UK and plans to announce results upon completion of the regulatory review.
Source: LB filings The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.